Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Happy birthday tilly, i watch from the sidelines here but really enjoy your light hearted banter...makes me smile which is more than i can say of some posts. Good luck with your sell robert but i have no idea why the board would want to dilute further unless necessary as it dilutes themselves, if that was the case would then not have just used full allotment from egm agreement. Personally i would really like to see assets at MT confirmed to JORC if this sale process drags out and further progress on rosego. EUA are slowly monopolising pgm resources in the area and this is why the first mover qoutes are so critical to long term value.
i think that is the position, i might be wrong but i think eua will have life after asset sale in some form. Mt etc will go and eua shell will remain either to trigger rosego options and/or collect divi. Why else set up a japanese director?
At these prices, as much as i want a pay day you have to wonder why doesnt a consortium with part buy in make sense. It starts to become too expensive a buy out otherwise. The medium to long term rewards would likely be fantastic and a reg dividend not far off our current mcap a not to un realistic outcome. Jap consortium i hope will outbid lowball offers received.
Now now, anyone expecting to get a quick return from this will be disappointed, i have timed my investments and selling poorly on faron largerly due to external factors requiring me to sell but im still here as believe in the companies philosophy and all we need is one of these drugs to be commercialised and we are away. The market has always reacted interestingly to faron so whilstbi had thought this might not get us back over 4 there is every chance some steading buying like we have seen previously will nudge this up.
Clearly bexi works to at least a significant degree and as others have said if dosing and less critical patients can be brought into the mix we have a life saving drug with an unmet clinical demand.. That is priceless and if i loose a few quid along the way it will have been worth it. Stay positive. Be more Marku
There are, like any valuation report, some assumptions here however i have, since its publication considered the report as the 'for sale sign offers over price' i dont expect the board to go for less than the min value.. As many others have said more elequently than i.. Values have gone up since the acf report and dfs etc has been completed
Likewise Green Man, i have some shares here but only started off with a few k a few years ago and i need EUA to make a serious investment here. ITs been all to quiet on the Faron front for too long, something brewing and i hope we have time on our side.
There has to be alot going on here in the background after the flurry of activity late spring early summer. Big farma clearly want to drown out the little guys as far as possible im just hoping those big farmas that dont have products come to some agreement with the likes of farn and sng and soon. For me this is about saving lives first, a payout would be a nice bonus. There is no doubt inf works even given a review of the information out there. And then there is the lord of the rings ....